Zentalis Pharmaceuticals is banking on small molecules for cancer—leaving the “cool technologies” aside for a “tried and true” approach, says the CEO, who wants to let the science speak for itself.... Read more »
Aurinia shares spiked last week after voclosporin, an immunosuppressant being tested in patients with lupus nephritis, met its primary and secondary endpoints in a Phase 3 study.
Aurinia Pharmaceuticals (NASDAQ: AUPH... Read more »
Palo Alto, CA-based BridgeBio Pharma (NASDAQ: BBIO) has named Eli Wallace as its chief scientific officer in residence for oncology. In this role, Wallace will oversee the company’s current drug... Read more »
The San Francisco-based drug discovery startup, Insitro, has hired its first chief data officer. Serafim Batzoglou joins the company from Illumina (NASDAQ: ILMN), out of San Diego, where he was... Read more »
After joining AstraZeneca’s Boston Bio Hub incubator last year, Gatehouse Bio is now teaming up with the pharma company to identify potential drug targets in respiratory and cardiovascular diseases.
Under the... Read more »
New biotech company Civetta Therapeutics has closed a $53 million Series A financing round to develop drugs that target “propeller proteins” as a way of treating cancers and other diseases.
Propeller... Read more »
Sight Diagnostics today announced it has received US FDA 510(k) clearance to use its patented OLO analyzer, which performs a complete blood count using two drops of blood.
The FDA clearance... Read more »
GHO Capital will use the money raised to invest in healthcare, including outsourced service providers, which are seeing demand from smaller biotechs, according to a Jefferies analyst.
GHO Capital raised €975... Read more »
Cambridge, MA-based Caraway Therapeutics has named Martin Williams as its CEO. Williams joins the company, which is looking to treat neurodegenerative diseases by preserving neurons, from Yuma Therapeutics where he was... Read more »
Cyrus Biotechnology and the Broad Institute of MIT and Harvard have teamed up to make gene editing with the CRISPR-Cas9 technology safer.
The multi-target collaboration, specific details of which are not... Read more »
Software startup Deep 6 AI has developed a system that analyzes a range of patient health records to accelerate the process of identifying candidates for clinical trial recruitment—a longstanding bottleneck in... Read more »
AstraZeneca has turned to Novoheart’s “human heart-in-a-jar” technology to create a preclinical model that mimics a form of heart failure for which there is no effective therapy available.
Based on Novoheart’s... Read more »
Off the heels of a $56 million Series B funding round, Cambridge, UK-headquartered Healx is looking to partner with rare disease patient groups to advance treatments toward the clinic.
The company’s... Read more »
Phoenix Molecular Designs, a biotech developing kinase inhibitors to treat cancer, has brought in an undisclosed amount of financing—boosting its total seed funding raised to $12 million.
The San Diego-based biotech... Read more »
Lucence, a genomic medicine company developing blood-based tests for cancer screening and treatment selection, announced this week the close of a $20 million Series A funding round led by IHH Healthcare.... Read more »
Tissium is targeting Boston’s biotech scene to advance its platform of proprietary biopolymers after building out its manufacturing capabilities in France.
Backed by a €38.75 million ($42.78 million) Series B funding... Read more »
Reata Pharmaceuticals on Tuesday closed a stock sale, raising $505.1 million to advance the company’s two lead drug candidates to regulatory review.
Reata’s stock price jumped last week after the company... Read more »
Novo Ventures has committed up to $25 million (€23 million) over a five-year period to fund seed-stage drug discovery projects at the Broad Institute of MIT and Harvard in a deal... Read more »
Underdog Pharmaceuticals has launched with nearly $4 million in seed funding to develop treatments for atherosclerosis, a progressive condition in which arteries become clogged with substances such as fats and cholesterol,... Read more »
Launched just last year, artificial intelligence-powered drug discovery company X-37 now has raised $14.5 million in Series A financing to expand its development programs.
Co-founded by Atomwise and a team from... Read more »